142 related articles for article (PubMed ID: 37850685)
1. Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.
Baumann L; Braun DL; Cavassini M; Stoeckle M; Bernasconi E; Schmid P; Calmy A; Haerry D; Béguelin C; Fux CA; Wandeler G; Surial B; Rauch A
Liver Int; 2024 Jan; 44(1):169-179. PubMed ID: 37850685
[TBL] [Abstract][Full Text] [Related]
2. Low hepatitis C virus-viremia prevalence yet continued barriers to direct-acting antiviral treatment in people living with HIV in the Netherlands.
Isfordink CJ; Smit C; Boyd A; de Regt MJA; Rijnders BJA; van Crevel R; Ackens RP; Reiss P; Arends JE; van der Valk M;
AIDS; 2022 May; 36(6):773-783. PubMed ID: 34999607
[TBL] [Abstract][Full Text] [Related]
3. A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study.
Braun DL; Hampel B; Ledergerber B; Grube C; Nguyen H; Künzler-Heule P; Shah C; Salazar-Vizcaya L; Conen A; Flepp M; Stöckle M; Béguelin C; Schmid P; Rougemont M; Delaloye J; Bernasconi E; Nicca D; Böni J; Rauch A; Kouyos RD; Günthard HF; Fehr JS
Clin Infect Dis; 2021 Oct; 73(7):e2194-e2202. PubMed ID: 32761122
[TBL] [Abstract][Full Text] [Related]
4. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
5. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
6. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
[TBL] [Abstract][Full Text] [Related]
7. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018.
Cotte L; Hocqueloux L; Lefebvre M; Pradat P; Bani-Sadr F; Huleux T; Poizot-Martin I; Pugliese P; Rey D; Cabié A;
Clin Infect Dis; 2021 Nov; 73(9):e3266-e3274. PubMed ID: 33400777
[TBL] [Abstract][Full Text] [Related]
8. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
9. Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men (PROBE-C Study).
Monin MB; Ingiliz P; Lutz T; Scholten S; Cordes C; Martínez-Rebollar M; Spinner CD; Nelson M; Rausch M; Bhagani S; Peters L; Reiberger T; Mauss S; Rockstroh JK; Boesecke C;
Clin Infect Dis; 2023 Feb; 76(3):e607-e612. PubMed ID: 36004410
[TBL] [Abstract][Full Text] [Related]
10. Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program.
Kusejko K; Salazar-Vizcaya L; Shah C; Stöckle M; Béguelin C; Schmid P; Ongaro M; Darling K; Bernasconi E; Rauch A; Kouyos RD; Günthard HF; Böni J; Fehr JS; Braun DL;
Clin Infect Dis; 2022 Nov; 75(10):1723-1731. PubMed ID: 35404384
[TBL] [Abstract][Full Text] [Related]
11. Viral hepatitis in persons living with HIV in the post-COVID era.
Soriano V; Moreno-Torres V; Mendoza C; Corral O; Barreiro P
AIDS Rev; 2023; 25(1):1-13. PubMed ID: 36952663
[TBL] [Abstract][Full Text] [Related]
12. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
[TBL] [Abstract][Full Text] [Related]
13. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
[TBL] [Abstract][Full Text] [Related]
14. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
[TBL] [Abstract][Full Text] [Related]
15. Decreasing prevalence and stagnating incidence of Hepatitis C-co-infection among a cohort of HIV-1-positive patients, with a majority of men who have sex with men, in Germany, 1996-2019.
Krings A; Schmidt D; Meixenberger K; Bannert N; Münstermann D; Tiemann C; Kollan C; Gunsenheimer-Bartmeyer B
J Viral Hepat; 2022 Jun; 29(6):465-473. PubMed ID: 35302675
[TBL] [Abstract][Full Text] [Related]
16. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.
Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH
Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.
Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H
Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914
[TBL] [Abstract][Full Text] [Related]
18. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression.
Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua NZ; Fierer DS; Chromy D; Rockstroh JK; Martin TCS; Ingiliz P; Hung CC; Dore GJ; Martinello M; Matthews GV
Lancet HIV; 2022 Jun; 9(6):e414-e427. PubMed ID: 35659336
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort.
Bregenzer A; Bruggmann P; Castro E; Moriggia A; Rothen M; Thurnheer MC; Vernazza P; Scheidegger C
Swiss Med Wkly; 2021 Mar; 151():w20460. PubMed ID: 33705563
[TBL] [Abstract][Full Text] [Related]
20. The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences.
Fursa O; Mocroft A; Lazarus JV; Amele S; Lundgren J; Matulionyte R; Rasmussen LD; Rockstroh JK; Parczewski M; Jilich D; Moreno S; Vassilenko A; Lacombe K; Wandeler G; Borodulina E; Brännström J; Wiese L; Orkin C; Behrens GMN; Mansinho K; Portu JJ; Peters L;
AIDS; 2022 Mar; 36(3):423-435. PubMed ID: 34690281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
